Mentari Therapeutics secures $200 million in a private placement to further its migraine prevention pipeline, backed by leading healthcare investors.
Amount Raised
$200 Million
Round Type
Post-IPO Equity
San FranciscoBiotechnologyHealth CareTherapeuticsDescription
Mentari Therapeutics has announced a $200 million private placement to support the development of its pipeline for migraine prevention. The funding will facilitate the continued advancement of targeted biologics. Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as the placement agents. This financing aims to enhance outcomes for individuals affected by migraines.
Who to call at Mentari Therapeutics, and when
A new round usually means Mentari Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Mentari Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mentari Therapeutics, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Mentari Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Mentari Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.